Current treatment modalities in active Crohn's disease

Italian Journal of Gastroenterology and Hepatology

Volumn 31, Issue 6, 1999, Pages 508-514

  Biancone, L ^a   Pallone, F ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Crohn's disease

Indexed keywords

ANTIINFECTIVE AGENT; AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; STEROID;

CONFERENCE PAPER; CROHN DISEASE; HUMAN; ORAL DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION;

CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS;

EID: 0032869756     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (84)

1. Sartor RB. Current concepts of the etiology and pathogenesis of Crohn's disease and ulcerative colitis. Gastroenterol Clin North Am 1995;24:475-508.
2. Targan SR, Murphy LK. Clarifying the causes of Crohn's disease. Nature Medicine 1995;1:1241-3.
3. Klein I, Reif S, Farbstein H, Halak H, Gilat TT. Preillness non-dietary factors and habits in Inflammatory Bowel disease. Ital J Gastroenterol Hepatol 1998;30:247-57.
4. Cottone M. Stress and physical activity: are they risk factors for inflammatory bowel disease? Ital J Gastroenterol Hepatol 1998;30:1252-3.
5. The natural history of Crohn's disease. A retrospective study. Ital J Gastroenterol 1978;10:97-9.
6. Ricci R, Di Paolo MC, Pallone F, Paoluzi P. Smoking and inflammatory bowel disease. Ital J Gastroenterol 1986;18:209-10.
7. Elton E, Hanauer SB. Review article: The medical management of Crohn's disease. Aliment Pharmacol Ther 1996;10:1-22.
8. Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol 1997;92:559-66.
9. Torsoli A, Pallone F, Boirivant M. A contribution to decision making in Crohn's disease. Ital J Gastroenterol 1983;15:138-9.
10. Pallone F, Mascioli F, Boirivant M, Tariciotti D, Torsoli A. A decision analysis study in Crohn's disease. Ital J Gastroenterol 1984;16:18-21.
11. Sacher DB, Andrews HA, Farmer RG, Pallone F, Pena S, Prantera C, et al. Proposed classification of patient subgroups in Crohn's disease. Working Team report. Gastroenterol Int 1992;3:141-54.
12. Boirivant M, Prantera C, Simi C, Fais S, Zannoni F, Torsoli A. Conservative management of small intestinal obstruction in Crohn's disease. Ital J Gastroenterol 1986;18:12-4.
13. Monsen U, Burnell P, Johansson C, Hellers G. Prevalence of inflammatory bowel disease among relatives of patients with Crohn's disease. Scand J Gastroenterol 1991;26:302-6.
14. Lashner BA, Evans AA, Kirsner JB, Hanauer SB. Prevalence and incidence of inflammatory bowel disease in family members. Gastroenterology 1986;91:1396-400.
15. Farmer RG, Michener WM, Mortimer EA. Studies of family history among patients with inflammatory bowel disease. Clin Gastroenterol 1980;9:1396-400.
16. Bayless TM, Tokayer AZ, Polito LM, Quaskey SA, Helliots ED, Harris ML. Crohn's disease: concordance for site and clinical type in affected family members - potential hereditary influences. Gastroenterology 1996;111:573-9.
17. Peeters M, Nevens H, Basert F, Hiele M, de Meyer AM, Vlietnick R, et al. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996;111:597-603.
18. Tysk C, Lindberg E, Jarnerot G, Floderus-Myhred B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988;29:990-6.
19. Best WR, Becktel LM, Singleton JW, Kern F. Development of a Crohn's Disease Activity Index. Gastroenterology 1976;70:439-44.
20. Pallone F, Ricci R, Boirivant M, Montano S. Measuring the activity of Crohn's disease. Ital J Gastroenterol 1981;13:51-3.
21. Summers RW, Switz DM, Sessions JT. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69.
22. Malkow H, Ewe K, Brandes JW. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
23. Lugering N, Kucharzik T, Stoll R, Domschke W. Current concepts of the role of monocytes/macrophages in inflammatory bowel disease. Balance of pro-inflammatory and immunosuppressive mediators. Am J Gastroenterol 1998;30:338-44.
24. Rosemberg JL, Lavin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975;20:721-6.
25. Ewe K, Press AG, Singe CC. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105:367-72.
26. O'Donoghue DP, Dawson AM, Powell-Tuck J, Brown RL, Lennard Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978;2:955-7.
27. Willoughby JMT, Kumar PJ, Beckett J, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2:994-7.
28. Singleton JW, Law DH, Kelley ML, Mekhiian HS, Sturdevant RA. National Cooperative Crohn's Disease Study. Adverse reactions to study drugs. Gastroenterology 1979;77:870-82.
29. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5.
30. Connell WR, Kamm MA, Dickson M, Balkwill AN, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52.
31. Alstead EM, Ritchie RK, Lennard-Jones JE, Farthing MJG, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990;99:443-6.
32. Campbell AC, Skinner JM, Hersey P. Immunosuppression in the treatment of inflammatory bowel disease. II. The effects of azathioprine on lymphoid cell populations in a double-blind trial in ulcerative colitis. Clin Exp Immunol 1976;24:249-58.
33. Hawthorne AB, Hawkey CJ. Immunosuppressive drugs in inflammatory bowel disease: a review of their mechanism of efficacy and place in therapy. Drugs 1989;38:267-88.
34. Present DH, Korelitz BJ, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long term randomized double blind study. N Engl J Med 1980;302:981-7.
35. Colonna T, Lorelitz BJ. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994;89:362-6.
36. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111:8641-9.
37. Haber CJ, Meltzer SJ, Present DH, Korelitz BI. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986;91:982-96.
38. Gross R, Scapa E. Hepatotoxicity of 6-mercaptopurine in Crohn's disease. Am J Gastroenterol 1992;87:1885-6.
39. Bernstein CN, Artinian L, Anton PA, Shanahan F. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Dig Dis Sci 1994;39:1638-41.
40. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine in childhood acute lymphoblastic leukemia. Lancet 1990;336:225-9.
41. Present DH. 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Gastroenterol Clin North Am 1989;18:57-71.
42. Miller LC, Cohen SE, Orencole SF. Interleukin-1 is structurally related to dihydrofolate reductase: effects of methotrexate on IL-1. Lymphokine Res 1988;7:272A.
43. Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993;38:1851-6.
44. Kozarek PA, Patterson DJ, Gelfand MD, Botoman VA, Ball T, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
45. Feagan BG, Rochon J, Fedorak RN. Methotrexate for treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
46. Bendtzen K, Petersen J. Effects of cyclosporine A (CyA) and methylprednisolone (MP) on the immune response. T-cell activating factor 1 (IL-1) abrogates CyA- but not MP-induced suppression of antigen-induced lymphokine production. Immunol Lett 1982;5:79-83.
47. Brynskov V, Freund L, Rasmussen SN. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active Crohn's disease. N Engl J Med 1989;321:845-50.
48. Brynskov J, Freund L, Campanini MC, Kampmann JP. Cyclosporine pharmacokinetics after intravenous and oral administration in patients with Crohn's disease. Scand J Gastroenterol 1992;27:961-7.
49. Jewell DP, Lennard-Jones JE. Oral cyclosporine for chronic active Crohn's disease: a multicentre controlled trial. The Cyclosporin Study Group of Great Britain and Ireland. Eur J Hepatol Gastroenterol 1994;6:499-505.
50. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporine A. Am J Gastroenterol 1993;88:646-9.
51. Reynolds JC, Treills DR, Abu-Elmagd K, Fung J. The rationale for FK506 in inflammatory bowel disease. Can J Gastroenterol 1993;7:208-10.
52. Derkx B, Taminiau P, Radema S, Stronkhorst A, Wortel C, Tytgat GNJ, et al. Tumour necrosis factor antibody treatment in Crohn's disease. Lancet 1993;342:173-4.
53. Van Dullemen HM, Van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat G, et al. Treatment of Crohn's disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
54. Targan SR, Hanauer SB, VanDeventer SJLK, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997;337:1029-35.
55. Debinski H, Forbes A, Kamm MA. Low-dose interferon-gamma for refractory Crohn's disease. Ital J Gastroenterol Hepatol 1997;29:403-5.
56. Pallone F, Fais S, Monteleone G. Commentary: Interferon-γ for treating Crohn's disease: do we know about what is helpful and what is harmful? Ital J Gastroenterol Hepatol 1997;29:406-8.
57. Dahlberg E, Thalen A, Brattsand R. Correlation between chemical structure, receptor binding and biological activity in some novel, highly active 16α-acetyl-substituted glucocorticoids. Mol Pharmacol 1984;25:70-8.
58. Greenberg GR, Feagan BG, Martin F and the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-41.
59. Lofberg R. Critical review: new steroids for inflammatory bowel disease. Inflamm Bowel Dis (CCFA Journal) 1995;1:135-61.
60. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol 1993;17:235-7.
61. Pallone F, Boirivant M, Fais S, Luzza F, Doldo P, Aloi A. Antibacterial drugs in Crohn's disease. Ital J Gastroenterol 1992;24:17-8.
62. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982;83:383-7.
63. Ursing B, Kamme C. Metronidazole for Crohn's disease. Lancet 1975;1:755-7.
64. Ursing B, Lam T, Barany F. A comparative study of metronidazole and sulfasalazine for active Crohn's disease. The Cooperative Crohn's Disease Study in Sweden. II. Result. Gastroenterology 1982;83:550-62.
65. Sutherland L, Singleton J, Sessions J. Double-blind placebo-controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-5.
66. Rutgeerts O, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
67. Norel CE. Effect of new quinolones on the human gastrointestinal microflora. Rev Infect Dis 1988;10:5193-6.
68. Solomon MJ, McLeod RS, O'Connor BI, Steinhart AH, Greenbert GR, Cohen Z. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. Can J Gastroenterol 1993;7:571-3.
69. Prantera C, Kihgna A, Zannoni F, Kohn A, Luzi C. Metronidazole plus ciprofloxacin in the treatment of active refractory Crohn's disease: results of an open study. J Clin Gastroenterol 1994;19:79-88.
70. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328-32.
71. Pallone F, Fais S, Squarcia O, Biancone L, Pozzilli P, Boirivant M. Activation of peripheral blood and intestinal lymphocytes in Crohn's disease: in vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut 1987;28:745-53.
72. Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997;112:1169-78.
73. Stack WA, Mann SD, Roy AJ. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997;349:521-4.
74. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
75. MacDonald TT, Hutchings TP, Choy MY, Murch S, Cooke A. Tumor necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-3.
76. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95.
77. Van Deventer SJ, Elson CO, Fedorak RN, Crohn's Disease Study Group. Multiple doses of intravenous interleukin-10 in steroid-refractory Crohn's disease. Gastroenterology 1997;113:383-9.
78. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, et al. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial. Gastroenterology 1993;104:1293-301.
79. Sanderson IR, Udeen S, Davies PSW. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 1987;61:123-7.
80. Raouf AH, Hildrey V, Daniel J. Enteral feeding as sole treatment for Crohn's disease: controlled trial of whole protein versus amino acid based feed and a case study of dietary challenge. Gut 1991;32:702-7.
81. Gonzalez-Hiux F, de Leon R, Fernandez-Banares F. Polymeric enteral diet as primary treatment of active Crohn's disease: A prospective steroid controlled trial. Gut 1993;36:778-82.
82. Griffiths AM, Ohlsson A, Sherman PM. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995;108:1056-67.
83. Lochs M, Steinhardt HJ, Kauls-Wentz B. Comparison of enteral nutrition and drug treatment in active Crohn's disease: results of the European Cooperative Crohn's Disease Study IV: Gastroenterology 1991;101:881-8.
84. Greenberg GR, Fleming CR, Jeejeebhoy KM. Controlled trial of bowel rests and nutritional support in the management of Crohn's disease. Gut 1988;29:1309-15.